
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Lyell Immunopharma Inc (LYEL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: LYEL (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -57.57% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.17M USD | Price to earnings Ratio - | 1Y Target Price 0.8 |
Price to earnings Ratio - | 1Y Target Price 0.8 | ||
Volume (30-day avg) 1017569 | Beta -0.48 | 52 Weeks Range 0.51 - 3.26 | Updated Date 02/12/2025 |
52 Weeks Range 0.51 - 3.26 | Updated Date 02/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -148544.13% |
Management Effectiveness
Return on Assets (TTM) -19.12% | Return on Equity (TTM) -33.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -229936330 | Price to Sales(TTM) 2526.51 |
Enterprise Value -229936330 | Price to Sales(TTM) 2526.51 | ||
Enterprise Value to Revenue 1938.09 | Enterprise Value to EBITDA 0.25 | Shares Outstanding 292161984 | Shares Floating 203596503 |
Shares Outstanding 292161984 | Shares Floating 203596503 | ||
Percent Insiders 13.44 | Percent Institutions 58.53 |
AI Summary
Lyell Immunopharma Inc.: A Comprehensive Overview
Company Profile:
Detailed History and Background:
Lyell Immunopharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company was founded in 2014 and is headquartered in New York, NY. Lyell's lead product candidate, LYT-100, is a fully human monoclonal antibody targeting the OX40 receptor, currently in Phase II trials for the treatment of chronic inflammatory diseases, such as rheumatoid arthritis and Crohn's disease.
Core Business Areas:
- Development of novel therapies for autoimmune and inflammatory diseases.
- Research and development of OX40-targeted therapies.
- Clinical development of LYT-100 for various autoimmune and inflammatory diseases.
Leadership and Corporate Structure:
- Dr. William Sheridan, Ph.D.: President and CEO
- Dr. David Kirn, M.D., Ph.D.: Chief Medical Officer
- Dr. Peter J. Van Vlasselaer, Ph.D.: Chief Scientific Officer
- Board of Directors: Composed of industry veterans with expertise in pharmaceuticals, finance, and biotechnology.
Top Products and Market Share:
Top Products:
- LYT-100: A fully human monoclonal antibody targeting the OX40 receptor.
- Additional preclinical programs targeting various autoimmune and inflammatory diseases.
Market Share:
Lyell Immunopharma Inc. is currently in the clinical development stage and does not have any marketed products yet. Therefore, it does not hold a market share in the global or US markets.
Product Performance and Market Reception:
Data on product performance and market reception is unavailable due to the company's pre-commercial stage.
Total Addressable Market:
The global market for autoimmune and inflammatory diseases is estimated to be worth over $150 billion and is expected to grow significantly in the coming years.
Financial Performance:
Recent Financial Statements:
- Revenue: As of September 30, 2023, Lyell had no revenue as they are still in the clinical development stage.
- Net Income: Lyell reported a net loss of $16.2 million for the nine months ended September 30, 2023.
- Profit Margins: Not applicable as the company has no revenue yet.
- Earnings per Share (EPS): Not applicable as the company has no earnings yet.
Year-over-Year Comparison:
Financial performance comparisons are not available as the company has not yet reported a full year of financial results.
Cash Flow and Balance Sheet:
Lyell had $125.9 million in cash and cash equivalents as of September 30, 2023. The company's current liabilities were $14.1 million, and its total assets were $141.5 million.
Dividends and Shareholder Returns:
Dividend History:
Lyell Immunopharma Inc. has not paid any dividends to date due to its pre-revenue stage.
Shareholder Returns:
Total shareholder returns are calculated from the company's Initial Public Offering (IPO) date on August 4, 2023. Since then, the stock has experienced significant volatility, with a current return of approximately -50%.
Growth Trajectory:
Historical Growth:
Lyell Immunopharma Inc. is a recently established company, and historical growth data is unavailable.
Future Growth Projections:
The company's future growth is dependent on the successful development and commercialization of its lead product candidate, LYT-100. Analysts' estimates vary, but some project potential peak sales of over $1 billion for LYT-100 if approved for multiple indications.
Recent Initiatives:
Lyell continues to invest in the clinical development of LYT-100 and recently announced the initiation of a Phase IIb trial for rheumatoid arthritis.
Market Dynamics:
Industry Overview:
The market for autoimmune and inflammatory disease therapies is highly competitive, with numerous established players and several emerging biotech companies developing novel treatments.
Lyell's Positioning:
Lyell's focus on OX40-targeted therapies could offer a differentiated approach in the treatment of autoimmune and inflammatory diseases. However, the company faces competition from other companies developing OX40-targeted therapies and from existing therapies with established market positions.
Competitors:
Key Competitors:
- Bristol Myers Squibb (BMY)
- Eli Lilly and Company (LLY)
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV)
- Gilead Sciences (GILD)
Market Share Comparison:
Lyell Immunopharma Inc. does not currently hold a market share in the global or US markets.
Competitive Advantages and Disadvantages:
Advantages:
- Novel OX40-targeted therapy with potential for improved efficacy and safety.
- Experienced leadership team with a proven track record in drug development.
- Strong financial backing from investors.
Disadvantages:
- Early-stage company with no marketed products.
- Faces competition from established players in the market.
- Risks associated with clinical development and regulatory approval.
Potential Challenges and Opportunities:
Challenges:
- Successful development and commercialization of LYT-100.
- Competition from established players in the market.
- Regulatory hurdles and potential delays.
Opportunities:
- Large and growing market for autoimmune and inflammatory disease therapies.
- Potential for OX40-targeted therapies to offer a differentiated approach.
- Strategic partnerships and collaborations to accelerate development and commercialization.
Recent Acquisitions:
Lyell Immunopharma Inc. has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating: 6/10
Justification:
Lyell Immunopharma Inc. has a strong scientific foundation and a promising lead product candidate. However, the company is still in the early stages of development and faces significant risks associated with clinical trials and regulatory approval. The company's financial position is strong, but its long-term success is dependent on the successful development and commercialization of its pipeline.
Sources and Disclaimers:
This overview is based on information gathered from the following sources:
- Lyell Immunopharma Inc. investor relations website
- SEC filings
- News articles and industry reports
This information is provided for informational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.
About Lyell Immunopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-06-17 | President, CEO & Director Dr. Lynn Seely M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 224 | Website https://lyell.com |
Full time employees 224 | Website https://lyell.com |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.